EIN Presswire: GlaxoSmithKline Featured Press Releases

How to best standardise imaging result from multi centre clinical trials

Tue, 10 Jan 2012 20:27:22 +0000

SMi present their 8th annual conference on.........
Imaging in Cancer Drug Development
14-15 March 2012, Copthorne Tara Hotel, London

/EINPresswire.com/ The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater. Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one. Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time. With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects?
Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.
Hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the drug development process. Find out how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardise imaging result from multi centre clinical trials.

Leading speakers include:

• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK

View the full programme and find out more details by contacting Andrew Gibbons on tel: +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk.

http://www.smi-online.co.uk/cancer-imaging38.asp

Understand the Strategies and developments in Pharmaceutical Parallel Trade

Tue, 18 Oct 2011 15:29:12 +0000

/EINPresswire.com/ SMi is proud to present their 6th annual Pharmaceutical Parallel Trade Conference, taking place on 6th & 7th February 2012 at the Copthorne Tara Hotel in London. This year's event will bring together expert speakers from different sectors within the industry, each with differing opinions and perspectives to offer. In such a rapidly developing field of parallel trade, it is essential that companies are kept up to date with the latest developments, regulations and strategies.

With the growth of parallel trade of pharmaceuticals in the European Union increasing consistently (despite numerous challenges from some of the industry's biggest players) this event is more relevant than ever. The principles of free movement of goods and the regional exhaustion of intellectual property rights, as well as the European Court of Justice consistently ruling in their favour on cases relating to trademark issues have led to great financial success for parallel traders. In response, pharmaceutical companies are now looking towards new solutions and strategies to address parallel trade, leading case studies of which will be discussed and presented at the 2012 conference.

Why should you attend this event?

• Hear about new techniques, strategies and developments in the field of parallel trade

• Understand the European directives and regulations

• Discuss risks that counterfeiting and repackaging in parallel trade may pose to patient safety

• Learn from multiple case studies demonstrating real life data and processes that work

• Develop strategies and techniques to limit the concerns and issues associated with parallel trade

• Network with key industry associates and solution providers to share valuable experiences

Key Speakers Include:

•Janice Haigh, Senior Director, Pricing & Market Access Europe, Astellas
•Eric Noehrenberg, Director, Public Affairs for Market Access, Shire Pharmaceuticals
•Nosh Lentin, Vice President of IT, UCB
•Gabriele Ghirlanda, Pricing & Reimbursement Manager, Boehringer Ingelheim
•Jim Thomson, Chairman, EAASM
•Heinz Kobelt, Secretary General, EAEPC
• Dermot Glynn, Chairman, Europe Economics

Visit our website here: http://www.smi-online.co.uk/2012paralleltrade18.asp

Alternatively or contact Ninica Hussain on: +44 (0) 20 7827 6115
e-mail: nhussain@smi-online.co.uk

**Book before 31st October 2011and Save £300**

About SMi Group

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk/pharma

Advances and Progress in Drug Design - Discover the latest developments

Tue, 18 Oct 2011 15:29:11 +0000

/EINPresswire.com/ SMi are proud to present the 11th annual Advances and Progress in Drug Design conference, taking place on 20th & 21st February 2012 at Copthorne Tara Hotel in London, UK. The number of pharmaceutical products entering the market has declined in the last decade. With the economic downturn and increasing threat from generic companies, pharmaceutical companies have never been under greater pressure to develop new innovative drugs. Many pharmaceutical and biotechnology companies are now searching for effective strategies to improve hit-to-lead conversion and to identify unsuccessful compounds early in the development process.

SMi's Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.

Why you should attend this conference

• Understand key strategies to increase the clinical success of your product

• Evaluate the design of allosteric modulators for the treatment of CNS disorders

• Discuss protein-protein interactions

• Identify novel targets in drug discovery

• Hear the latest in rational drug design

• Understand how computational tools can be used to reduce drug toxicity

• Use this as a platform to further your understanding of this field

Speakers presenting at this year's event include...

• Mike Hann, Director of Bio-Molecular Structure, GSK
• Jerome Amaudrut, Senior Scientist in Computer-Aided Drug Design, Abbott
• John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
• Matthias Frech, Head of Molecular Interaction & Biophysics, Merck
• Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer

**Book before 31st October 2011and Save £300**

Visit our website here: http://www.smi-online.co.uk/2012drugdesign20.asp
Alternatively contact Ouasie Abdel-Razig on +44 (0) 20 7827 6734 or e-mail: oabdelrazig@smi-online.co.uk

About SMi Group

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk/pharma

Europe's Leading Pre-Filled Syringes conference

Tue, 18 Oct 2011 15:29:09 +0000

/EINPresswire.com/ Europe's Leading Pre-Filled Syringes conference, taking place on 18th & 19th January 2012 at Marriott Regents Park in London, UK

Now in its 4th year it promises to be bigger and better! Building on the continual success of both our European and Asia Pacific events, this year's agenda will provide an unparalled opportunity for debate and problem solving of key challenges currently facing the parenteral market.

With a reputation for attracting the industry's leading figures, this year's forum will look at key areas including device development and the design concept; secondary packaging and quality assurance; technological and regulatory updates and will provide essential advice on how to create strategies for future commercial success. Providing an indepth market overview, whilst delivering insightful looks into regulatory considerations, formulations and sterilization; this year's event promises to be the best yet!

The conference will address

• Secondary Packaging - Process and manufacturing

• Entry Level Machines - The benefits of high value and low volume

• Needle safety - EU guidelines and planning for needle prick injuries

• Market Perspectives Technology Trends - Preparing for the future of advanced injection technologies, new technology developments and safety devices

• Regulatory Considerations Expectations - US & EU regulatory updates, considerations and strategies

• Glass v Plastic - Tackling glass breakages and silicon distribution

• Development & Manufacturing Considerations - PFS formulation, manufacturing considerations and inspection strategies

• Networking - Share valuable experiences and network with key industry figures

Key Speakers Include

•David Post, Director of Device CMC, Abbott
•Sandeep Nema, Executive Director, Pfizer
•Raul Soikes, Senior Director of Program Management, Baxter
•Scott Brown, Device Development Lead, Merck
•Karoline Bechtold-Peters, Head, Clinical Manufacturing, Roche
•Daniel Wheeler, Consultant Anaesthetist, University of Cambridge

Visit our website here:
http://www.smi-online.co.uk/2012prefilledsyringes23.asp

Alternatively contact Ouasie Abdel-Razig on +44 (0) 20 7827 6734
or e-mail: oabdelrazig@smi-online.co.uk

**Book before 31st October 2011 and Save £100**

About SMi Group

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk/pharma

Biomarkers Summit - Discovery, Development & Therapeutics

Tue, 18 Oct 2011 15:29:08 +0000

/EINPresswire.com/ SMi proudly presents their 5th annual Biomarkers Summit, taking place on 16th & 17th January at Copthorne Tara Hotel in London, UK.

This year's exciting event will provide a complete picture of developments in the biomarkers field, looking at biomarker development, discovery validation, as well as technological and regulatory updates and advice. Progress of research into therapeutic areas such as oncology, neurodegenerative and respiratory diseases, as well as diabetes will also be discussed.

SMi's Biomarkers Summit 2012 will provide a unique opportunity for debate and problem solving for key challenges facing the biomarkers fields and will present a fantastic platform for networking with senior executives for the pharmaceutical industry.

With biomarkers becoming the most effective tool in drug discovery and development, it is vital that you are kept up-to-date with advances in the field. The 2012 speaker panel consisting of key industry professionals presenting on their expertise in biomarker research, as well as commercialization strategies will equip attendees with the essential information required to succeed in this rapidly developing field.

Key topics to be discussed include:

• Translational biomarkers: Use as a decision making tool in early clinical drug development, development of techniques to identify biomarkers and prediction using PK/PD modelling

• Biomarkers in immunology: Novel inhibitors for use in autoimmune disease, reducing risk in clinical trials and evaluating precision medicine

• Developing neuroscience drugs: Using central activity biomarkers, considering prognostic and diagnostic properties, the benefits of cerebrospinal fluid biomarkers

• Imaging techniques: Establishing pharmcodynamic factors, imaging modalities and discussing what is necessary to validate a biomarker

• Oncology biomarkers: Theranostic development, personalized cancer treatment and patient stratification in oncology biomarker validation

Key Speakers Include:

• Hans Winkler, Senior Director & Global Head, Johnson & Johnson
• Huseyin Mehmet, Director, Exploratory Biomarkers, Merck
• Terry Walker, Director, Translational Immunology, Pfizer
• Gary Gilmour, Senior Research Scientist, Eli Lilly
• Darren Hodgson, Biomics Advisor, AstraZeneca
• Meagan Myers, Staff Fellow, US FDA

Visit our website here: http://www.smi-online.co.uk/biomarkers22.asp
Alternatively or contact Ninica Hussain on: +44 (0) 20 7827 6115
e-mail: nhussain@smi-online.co.uk

About SMi Group

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
For further information, contact:
Ninica Hussain
Tel: +44 (0) 20 7827 6115
Email: nhussain@smi-online.co.uk

SMi's 10th annual Clinical Trials in CNS, 23rd & 24th November 2011

Tue, 18 Oct 2011 15:29:06 +0000

/EINPresswire.com/ SMi's 10th annual Clinical Trials in CNS conference will be an ideal platform for leading industry experts to discover the current and future opportunities within the essential field of CNS drug development. This conference will address current clinical drug discovery activities, as well as innovative and effective drug development strategies and potential problems often faced in clinical trials.

This conference will focus on a wide range of therapeutic areas such as Multiple Sclerosis, Parkinson's and Alzheimer's, as well as considering a multitude of psychiatric disorders with in-depth discussions and case study presentations from the key industry players.

As such a fast-progressing and important field, it is vital that you are kept up to date with the latest developments and advances in CNS Clinical Trials, such as novel translational research studies. This conference will offer a unique opportunity for you to learn about the field from key opinion leaders and will present a fantastic platform for networking with senior executives from the pharmaceutical industry.

Key topics to be addressed:

• Cognition enhancement

• Latest developments in MS, PD and AD clinical development

• Biomarkers and CNS clinical trials

• Participant recruitment and retention issues in CNS clinical trials

• Schizophrenia and depression: specific considerations.

• Efficacy predictions

• Current challenges in translational CNS research

• Facilitating and establishing industry and academic partnering

• Early phase development trials in CNS

Hear keynote addresses from:

• Hitendra Parmar, European Medical Director for Alzheimer's Disease, Pfizer

• Georg Terstappen, Director and Department Head, Neuroscience Discover, Abbott

• Sophie Dix, Senior Research Scientist, Neurodegenerative Diseases Drug Hunting Team, Lilly

• Florien von Raison, Head of Global Clinical Development Unit, Parkinson's Diseases, Merck Serono

• Chas Bountra,Chief Scientist, Structural Genomics Consortium, Univeristy of Oxford

• Simon Ridley, Head of Research, Alzheimer's Research UK

Visit http://www.smi-online.co.uk/2011cnstrials36.asp to reserve your place. Alternatively, contact Asma Bibi at Tel: +44 (0) 207 827 6736 or
Email: abibi@smi-online.co.uk.

About SMi Group
Clinical Trials in CNS is just one of the many conferences that are a part of the SMi Group portfolio.
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
For further information, contact:
Asma Bibi
Tel: +44 (0) 207 827 6736
Email: abibi@smi-online.co.uk

Firminite Natural Male Enhancement Pill Gains Endorsement by Leading Erectile Dysfunction Specialist

Thu, 24 Mar 2011 11:35:41 +0000

ALLEN, TX—(EIN PRESSWIRE—March 24th, 2011)—West Coast Nutritionals, LLP - the makers of the natural male enhancement pill, Firminite (online at www.Firminite.com) - is pleased to announce the endorsement of it by leading Erectile Dysfunction Specialist, Dr. Charles Runels, M.D. Firminite has the full endorsement and recommendation of Dr. Runels, a practicing, licensed, nationally known and recognized medical doctor specializing in erectile dysfunction (ED).

"When I first started testing the final formulation for the Firminite natural male enhancement pill, I started with one of my most difficult to treat patients," Dr. Runels says of his initial trials with supplement. "He had a great libido and felt wonderful after hormonal therapy, but even with testosterone, and Growth Hormone, and Viagra, he still had difficulties with erectile dysfunction."

Firminite provided a safe and effective, natural solution for Runels' patient.

"He had tried every supplement he could buy and every prescription remedy I could find. But two tablets of Firminite did the trick," Runels explains. "His wife was in my office two days later wanting more samples before they went on vacation."

Runels infers that there are natural alternatives to the popular and commonly prescribed ED drugs. "The good news is that thanks to a breakthrough natural male enhancer and impotence alternative called Firminite, you don't have to suffer with this common problem any more," he says.

Dr. Runels speaks very positively about his endorsement of the male enhancement supplement, which he not only wholeheartedly endorses, but which he also recommends to any of his patients who are currently suffering from erectile dysfunction.

"Since I started recommending the all Natural Male Enhancer Plus Medical Grade Potency, Firminite, to all of my patients," Runels says, "I hardly write any prescriptions for those blue pills [popular ED drugs] any more."

He concludes, "As a medical professional, I wholeheartedly recommend Firminite to all of my ED patients."

About: Firminite is a male enhancement pill that can be taken on an as-needed basis and is considered to be the best alternative to ED drugs. Firminite has no reported side effects and can also work effectively when taken with alcohol.

Firminite is recommended by leading doctors and institutes - including an endorsement by renowned Erectile Dysfunction Specialist, Dr. Charles Runels, M.D. In 2000, Dr. Runels founded the Runels Center for Lifelong Health, where he currently practices Internal Medicine, Endocrinology, and Clinical Trials. He is an active member of the Academy of Pharmaceutical Physicians and Investigators, and also is a member of the Association of Clinical Research Professionals.

Firminite is an herbal supplement. The FDA does not recognize the practice of herbs. The Food and Drug Administration (FDA) has not evaluated any statement made herein. None of the information provided is meant to act as a prescription, medical advice or therapeutic advice. Firminite is not intended to diagnose, treat, cure or prevent any disease.

Press Contact:
Scott Miller
Online Web Director
Email: support@firminite.com
Phone: (877) 782-6464
Web: www.firminite.com
Address: P O Box 253 Allen, TX 75013.

Emergo Group to Provide Full Clinical Trial Support Services in Japan

Tue, 08 Mar 2011 15:13:03 +0000

Emergo Group now offers comprehensive clinical trial management and support in Japan through partnership with NTT Data Group.

/EINPresswire.com/ TOKYO, JAPAN - Emergo Group, a leading medical device quality assurance and regulatory affairs consulting firm, has formed a strategic partnership with Data Pharma Co. Ltd. to provide full clinical trial management services in Japan. Data Pharma is the Clinical Research Organization (CRO) subsidiary of Tokyo-based NTT Data Group.

Emergo Group's office in Tokyo, Emergo Japan K.K., will offer comprehensive clinical trial management services to assist medical device manufacturers. The move comes in response to a growing need for medical device manufacturers to demonstrate the efficacy of their products through clinical trials conducted in Japan.

Michiharu Miyahara, President and CEO of Emergo Japan K.K. notes: "The Japanese government has a strategy to drive growth in the life sciences industry, but this has been challenging due to the complexity of conducting clinical trials in Japan which are sometimes needed to obtain regulatory approval. There are very few consultancies specializing in medical device clinical trials in Japan so we are addressing this growing need. Our team is eager to start helping manufacturers conduct clinical trials for their products prior to commercialization in Japan."

Japan's Pharmaceutical and Medical Devices Agency (PMDA) requires clinical trials in cases where a medical device's safety and efficacy cannot be evaluated using existing literature or non-clinical evidence, as well as for high-risk devices. The PMDA sometimes accepts clinical trial results obtained outside Japan, provided those results conform to the country's equivalency standards.

Emergo Japan and Data Pharma provide clinical trial management consulting and CRO-related services respectively for both foreign and Japanese medical device clients.

About Emergo Group
Emergo Group is a medical device regulatory consulting firm providing a wide range of services for device registration, QMS compliance, clinical trial management, in-country representation, reimbursement and distribution consulting. Emergo Group has more than 1500 clients manufacturing a wide range of medical devices and IVDs. Offices worldwide. www.emergogroup.com

About Data Pharma
Data Pharma, a member of NTT Data Group, is a contract research organization supporting more than 100 health care institutions across Japan. Supporting both medical device and pharmaceutical clinical trials, Data Pharma also offers data management and statistical analysis services.

Stewart Eisenhart
512-327-9997
www.emergogroup.com

PR Courtesy of Online PR Media: http://bit.ly/ei2taP

Scientific Disclosure Ethics Questioned in Diabetes Drug Debate

Fri, 19 Mar 2010 10:13:24 +0000

March 19, 2010 /EIN PRESSWIRE/ The relationship between the scientific community and pharmaceutical companies is coming under fire again.

At the center of the most recent black eye is the diabetes drug Avandia. The immensely popular drug was linked with an increased risk of heart attacks in research published in 2007. Since the findings, the scientific community has largely come to the defense of the drug, but a new report suggests a growing concern with conflict of interest between scientists and pharmaceutical companies.

Researchers from the Mayo Clinic analyzed more than 200 articles published after 2007 in scientific journals, which commented on the heart-attack risk associated with Avandia. They found 47% of the study authors had financial conflicts of interest, but 23% of them not disclose it.

The Mayo study says 94% of the authors who had positive views about Avandia had financial links with pharmaceutical companies and 87% had financial links with the drug's manufacturer, GlaxoSmithKline.

Of the 29 articles strongly recommending the rival Eli Lilly drug, Actos, as a replacement for Avandia, 25 were by authors with financial links to Lilly.

Read more at Pharmaceutical Industry Today:

Avandia news - http://pharmaceuticals.einnews.com/news/avandia
Actos news - http://pharmaceuticals.einnews.com/news/actos

Located at http://pharmaceuticals.einnews.com, Pharmaceutical Industry Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest pharmaceutical news from around the world, saving them valuable time they'd spend searching for information. New users to Pharmaceutical Industry Today can enjoy a no-obligation, one-week free trial.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.